Actively Recruiting
ELEVATE A Global Patient Registry to Track the Natural History and Real-World Treatment of Acute Hepatic Porphyria
Led by Alnylam Pharmaceuticals · Updated on 2026-04-27
150
Participants Needed
30
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are conducting a global patient registry to better understand the natural history and real-world clinical management of patients with Acute Hepatic Porphyria AHP. This observational study also aims to gather information on the real-world safety and effectiveness of givosiran and other approved treatments for AHP. The registry is sponsored by Alnylam Pharmaceuticals and includes patients diagnosed with AHP. Participants with AHP will be enrolled and managed according to their usual clinical care without any assigned interventions by the study. The study collects data over time to observe how patients are treated in routine practice and how their condition progresses. There are no experimental treatments given as part of this registry. During the study, researchers will track the occurrence of selected events of interest related to AHP for up to six years. They will also monitor the annual rate of porphyria attacks and assess patients quality of life using the 12-Item Short Form Health Survey Version 2. Participants will be followed prospectively to provide ongoing information about their health and treatment outcomes.
CONDITIONS
Brief Title
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here